Profile data is unavailable for this security.
About the company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
- Revenue in USD (TTM)5.15bn
- Net income in USD-5.97bn
- Incorporated2016
- Employees5.60k
- LocationModerna Inc325 BINNEY STREETCambridge 02142United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
- Websitehttps://www.modernatx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON PLC | 8.23bn | 683.12m | 26.02bn | 41.10k | 38.19 | 2.76 | 20.44 | 3.16 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| DuPont de Nemours Inc | 11.98bn | 404.00m | 33.41bn | 24.00k | 91.47 | 1.42 | 20.83 | 2.79 | 0.8736 | 0.8126 | 27.12 | 56.41 | 0.3036 | 3.37 | 4.99 | 499,208.30 | 1.12 | 0.3709 | 1.24 | 0.468 | 35.15 | 35.69 | 3.70 | 1.97 | 1.61 | 6.24 | 0.2446 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
| Biogen Inc | 9.66bn | 1.17bn | 33.57bn | 7.57k | 28.81 | 2.21 | 19.78 | 3.47 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Gartner Inc | 5.97bn | 797.23m | 34.95bn | 20.29k | 44.81 | 49.03 | 35.27 | 5.85 | 10.05 | 10.05 | 75.24 | 9.18 | 0.7915 | -- | 3.80 | 295,054.30 | 10.57 | 8.24 | 19.95 | 14.76 | 67.72 | 67.55 | 13.35 | 12.20 | -- | 13.10 | 0.7738 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
| Iqvia Holdings Inc | 15.07bn | 1.36bn | 42.12bn | 87.00k | 31.54 | 6.64 | 16.89 | 2.80 | 7.33 | 7.33 | 81.34 | 34.82 | 0.5761 | -- | 4.64 | 173,206.90 | 5.19 | 3.24 | 6.93 | 4.07 | 35.03 | 34.32 | 9.01 | 6.03 | -- | 3.19 | 0.6809 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Moderna Inc | 5.15bn | -5.97bn | 50.93bn | 5.60k | -- | 3.97 | -- | 9.88 | -15.66 | -15.66 | 13.51 | 33.46 | 0.2523 | 7.78 | 8.24 | 920,178.60 | -29.22 | 20.95 | -34.13 | 29.51 | 22.43 | -- | -115.82 | 32.10 | 3.91 | -- | 0.0429 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Mar 2024 | 44.66m | 11.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 37.62m | 9.83% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 17.13m | 4.48% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 14.45m | 3.78% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 12.76m | 3.33% |
| Th�l�me Partners LLPas of 31 Mar 2024 | 7.32m | 1.91% |
| Geode Capital Management LLCas of 31 Mar 2024 | 6.75m | 1.76% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 5.60m | 1.46% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 3.65m | 0.95% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.49m | 0.91% |
